The flavored variant of the product includes organic stevia extracts as well as the essential oils. The products also offer a wide range of CBD tinctures in terms of its tincture strength which can range anywhere between 250 milligrams and 1,000 milligrams. Potential buyers can access the certificates of analyses online for all the varieties available.
Each bottle of CBD oil provides 30 servings and buyers can check the pros and cons of each of the ingredients used in the product online. As a manufacturer of one of the most well-known CBD brands, Joy Organics’ products have time and again exhibited their efficacy as a provider of relief from sleep disorders, and pain and anxiety issues.
It’s evident that a diverse variety of CBD oil products is available in the market that can interact with and supercharge the endocannabinoid system of our body. It helps us with sleep disorders and reduces the pain and anxiety.
Veritas Farms Full Spectrum CBD Tincture
With so many benefits associated with its use, it’s no wonder that the market of CBD oil is projected to grow at an astounding rate of 31.90% between 2020 and 2027. However, with a growing market comes the problem of plenty. Therefore, we have prepared a list of the seven best CBD oils based on their efficacy to relieve stress, pain, sleep, and anxiety disorders, the levels of safety and testing they adhere to, and the volume of positive feedback they have managed to garner from end-users.
The organically extracted hemp is replete with the requisite volume of essential oils, trade cannabinoids, phytochemicals, and terpenes. The product contains 1000mg of CBD and 90mg of CBN per bottle. Adding to their repute, this blueberry lavender flavored tincture is testified by a certificate of analysis from the highly reputed DB Labs.
Like its other counterparts mentioned in the list, Charlotte’s Web provides full disclosures of the product in terms of putting up the certificate of analysis online.
Populum Full-Spectrum Hemp CBD Oil
CBD Oils manufactured by Calm by Wellness are considered to be the absolute best to provide relief from pain, anxiety, and sleep woes.
Charlotte’s Web CBD oil features at number four on the list with its assorted offering of a wide range of useful phytocannabinoids along with a robust variety of cannabinoid compounds like CBC, CBD, and CBG. It is a full-spectrum oil prepared by extracting the full plant.
Results: The final sample consisted of 72 adults presenting with primary concerns of anxiety (n = 47) or poor sleep (n = 25). Anxiety scores decreased within the first month in 57 patients (79.2%) and remained decreased during the study duration. Sleep scores improved within the first month in 48 patients (66.7%) but fluctuated over time. In this chart review, CBD was well tolerated in all but 3 patients.
Design: A large retrospective case series at a psychiatric clinic involving clinical application of CBD for anxiety and sleep complaints as an adjunct to usual treatment. The retrospective chart review included monthly documentation of anxiety and sleep quality in 103 adult patients.
Conclusion: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.
Conflict of interest statement
Context: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature.
Objective: To determine whether CBD helps improve sleep and/or anxiety in a clinical population.
Main outcome measures: Sleep and anxiety scores, using validated instruments, at baseline and after CBD treatment.
Dr Shannon has published several professional books on integrative mental health. Dr Shannon is a Principal Investigator for a Phase 3 study of 3,4-methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy for severe posttraumatic stress disorder and receives compensation for his clinical work from the Multidisciplinary Association for Psychedelic Studies, Santa Cruz, CA. The other authors have no conflicts of interests to disclose.